INT12095

From wiki-pain
Revision as of 08:05, 21 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1989
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 26
Total Number 26
Disease Relevance 12.01
Pain Relevance 8.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Edn1) extracellular region (Edn1) cell-cell signaling (Edn1)
cytoplasm (Edn1)
Anatomy Link Frequency
plasma 2
cardiomyocytes 1
oocytes 1
blood 1
myocytes 1
Edn1 (Mus musculus)
Pain Link Frequency Relevance Heat
Kinase C 42 100.00 Very High Very High Very High
Pain 31 100.00 Very High Very High Very High
antagonist 30 100.00 Very High Very High Very High
Morphine 18 100.00 Very High Very High Very High
analgesia 4 100.00 Very High Very High Very High
Antinociceptive 15 99.96 Very High Very High Very High
Paracetamol 2 99.84 Very High Very High Very High
nMDA receptor antagonist 4 99.80 Very High Very High Very High
diclofenac 1 99.80 Very High Very High Very High
tolerance 9 99.20 Very High Very High Very High
Disease Link Frequency Relevance Heat
Diabetes Mellitus 127 100.00 Very High Very High Very High
Pain 19 100.00 Very High Very High Very High
Heart Rate Under Development 23 99.84 Very High Very High Very High
Pruritus 1 99.76 Very High Very High Very High
Injury 165 99.68 Very High Very High Very High
Increased Venous Pressure Under Development 92 99.08 Very High Very High Very High
Angina 6 98.64 Very High Very High Very High
Microvascular Angina 1 98.60 Very High Very High Very High
Nociception 8 98.44 Very High Very High Very High
Irritable Bowel Syndrome /

Irritable Bowel Syndrome Super / Visceral Pain

2 98.40 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The opioid receptor antagonist naloxone did not antagonize, and the cyclooxygenase inhibitors indomethacin and diclofenac slightly inhibited the ET-1 effect.
Negative_regulation (inhibited) of ET-1 associated with antagonist, narcan, opioid receptor and diclofenac
1) Confidence 0.59 Published 1992 Journal Methods Find Exp Clin Pharmacol Section Abstract Doc Link 1625506 Disease Relevance 0 Pain Relevance 0.44
On the average, ET-1 levels decreased by 21 % after pamidronate infusions (p = 0.045).
Negative_regulation (decreased) of ET-1
2) Confidence 0.51 Published 2005 Journal Exp. Clin. Endocrinol. Diabetes Section Abstract Doc Link 16320159 Disease Relevance 0.56 Pain Relevance 0.07
In group 1, the ET-1 level decreased significantly at second blood samplings (2.5+/-0.4 pmol/L versus 1.7+/-0.6 pmol/L, P <.001), whereas there were no definite changes of ET-1 levels in group 2 (2.5+/-0.5 pmol/L versus 2.6+/-0.6 pmol/L, P =not significant).
Negative_regulation (decreased) of ET-1 in blood
3) Confidence 0.48 Published 2001 Journal Ann Emerg Med Section Body Doc Link 11326179 Disease Relevance 0 Pain Relevance 0
After delivery the maternal ET-1 level decreased gradually and 2 day postpartum ET-1 levels reached the normal non-pregnant level.
Negative_regulation (decreased) of ET-1
4) Confidence 0.46 Published 1990 Journal Gynecol. Endocrinol. Section Abstract Doc Link 2204252 Disease Relevance 0.24 Pain Relevance 0.24
CNQX, a non-NMDA receptor antagonist, did not inhibit the ET-1 effects.
Negative_regulation (inhibit) of ET-1 associated with nmda receptor antagonist
5) Confidence 0.43 Published 1996 Journal Pain Section Abstract Doc Link 8826508 Disease Relevance 0.25 Pain Relevance 0.65
Furthermore, the antinociceptive effect of ET-1 in diabetic mice was decreased when the doses of ET-1 were increased.
Negative_regulation (decreased) of ET-1 associated with diabetes mellitus and antinociceptive
6) Confidence 0.43 Published 1993 Journal Res. Commun. Chem. Pathol. Pharmacol. Section Abstract Doc Link 8451542 Disease Relevance 0.72 Pain Relevance 0.49
Prazosin, an alpha 1-adrenergic blocking agent, also prevented the ET-1 antinociceptive effect.
Negative_regulation (prevented) of ET-1 associated with antinociceptive
7) Confidence 0.42 Published 1996 Journal Pain Section Abstract Doc Link 8826508 Disease Relevance 0.24 Pain Relevance 0.65
The effect of big-ET-1[1-38], but not ET-1, was blocked by pretreatment with the enzyme inhibitor phosphoramidon (10 mg/kg, s.c., 30 min prior), implying that the big-ET-1[1-38] must first be enzymatically cleaved, presumably to ET-1, in order to elicit the abdominal constriction response.
Negative_regulation (blocked) of ET-1
8) Confidence 0.42 Published 1991 Journal Life Sci. Section Abstract Doc Link 1826753 Disease Relevance 0.09 Pain Relevance 0.30
This test might also serve as a discriminative antinociceptive screen, because the response to ET-1 was not blocked by acetaminophen (400 mg/kg, p.o.), ibuprofen (75 mg/kg, p.o.) or indomethacin (1.0 mg/kg, p.o.).
Negative_regulation (blocked) of ET-1 associated with paracetamol and antinociceptive
9) Confidence 0.42 Published 1991 Journal Life Sci. Section Abstract Doc Link 1826753 Disease Relevance 0.07 Pain Relevance 0.31
Both YM598 and atrasentan (0.3 to 3 mg/kg, p.o.) significantly inhibited the endothelin-1 (10 pmol/paw)-induced potentiation of nociception in a dose-dependent manner.
Negative_regulation (inhibited) of endothelin-1 in paw associated with nociception
10) Confidence 0.42 Published 2004 Journal Eur. J. Pharmacol. Section Abstract Doc Link 15178362 Disease Relevance 1.23 Pain Relevance 0.70
That is, at equieffective doses, a 60-min prior i.p. injection of ET-1 blocked the behavioral response to a subsequent i.p. injection of ET-1 or PpQ, but not of ACh, whereas a 60-min prior injection of ACh or of PpQ had no effect on a subsequent i.p. injection of ACh, PpQ or ET-1.
Negative_regulation (injection) of ET-1
11) Confidence 0.41 Published 1996 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 8764328 Disease Relevance 0.13 Pain Relevance 0.12
The purpose of this study was to evaluate the plasma ET-1 levels and CFVR in patients with chest pain but without coronary artery disease (CAD).
Negative_regulation (evaluate) of ET-1 in plasma associated with angina and coronary artery disease
12) Confidence 0.38 Published 2005 Journal Hypertens. Res. Section Abstract Doc Link 16555580 Disease Relevance 1.13 Pain Relevance 0.56
A myristoyl-tagged membrane-permeant-protein kinase Cepsilon V1-2 inhibitory peptide also significantly suppressed the enhancing effect of endothelin-1.
Negative_regulation (effect) of endothelin-1
13) Confidence 0.37 Published 2006 Journal Neuroscience Section Abstract Doc Link 16298080 Disease Relevance 0.31 Pain Relevance 0.52
The ET-1 induced constrictions in mice were prevented by indomethacin.
Negative_regulation (prevented) of ET-1
14) Confidence 0.36 Published 1989 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 2473319 Disease Relevance 0.46 Pain Relevance 0.25
ET-1-induced pain-like behavior was attenuated by an endothelin type A receptor antagonist but not by PKC inhibitors and was also attenuated in TRPV1-deficient (KO) mice.
Negative_regulation (attenuated) of ET-1-induced associated with pain, kinase c and antagonist
15) Confidence 0.32 Published 2009 Journal Neuroreport Section Abstract Doc Link 19202458 Disease Relevance 0.54 Pain Relevance 0.84
Endothelin-converting enzyme-1 (ECE-1) is responsible for the cleaving of big ET-1 between the Trp21 and Val22 residues, ultimately leading to the formation of ET-1 [56].
Negative_regulation (formation) of ET-1
16) Confidence 0.26 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2913859 Disease Relevance 0.42 Pain Relevance 0.07
In infected mice in which the gene for ET-1 was deleted in cardiomyocytes, there was a reduction in myocardial inflammation and fibrosis [79].
Negative_regulation (deleted) of ET-1 in cardiomyocytes associated with myocarditis, fibrosis and inflammation
17) Confidence 0.18 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2930857 Disease Relevance 1.19 Pain Relevance 0.20
The OVA challenge-induced IFN-gamma and ET-1 productions were inhibited in IL-18(-/-) immunized mice, as well as ET-1 production in IFN-gamma(-/-) immunized mice.
Negative_regulation (inhibited) of ET-1
18) Confidence 0.13 Published 2007 Journal Brain Behav. Immun. Section Abstract Doc Link 17194566 Disease Relevance 0.27 Pain Relevance 0.39
The complex interactions between myocytes and nerves in pathologic states provide insights into the disappointing results of ET-1 blockade in congestive heart failure and yield new pharmacologic targets for the future [199].
Negative_regulation (blockade) of ET-1 in myocytes associated with heart rate under development
19) Confidence 0.09 Published 2010 Journal The Open Biochemistry Journal Section Body Doc Link PMC2864432 Disease Relevance 0.64 Pain Relevance 0
We provide evidence for the first time that endothelin antagonists can restore morphine analgesia in morphine-tolerant rats and prevent the development of tolerance to morphine.
Negative_regulation (prevent) of endothelin associated with antagonist, tolerance, analgesia and morphine
20) Confidence 0.08 Published 2004 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 15838261 Disease Relevance 0.07 Pain Relevance 1.43

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox